Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized trial comparing preservation of function status after either Medpulser electroporation with intratumoral bleomycin therapy [Selective Electrochemical Tumor Ablation, SECTA; Inovio Biomedical Corporation] or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the base of the tongue, posterior lateral pharyngeal wall, hypopharnyx, or larynx that have failed primary curative therapy

Next Previous
Trial Profile

A randomized trial comparing preservation of function status after either Medpulser electroporation with intratumoral bleomycin therapy [Selective Electrochemical Tumor Ablation, SECTA; Inovio Biomedical Corporation] or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the base of the tongue, posterior lateral pharyngeal wall, hypopharnyx, or larynx that have failed primary curative therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bleomycin (Primary)
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 11 Oct 2018 Planned End Date changed from 1 May 2009 to 1 Jun 2007.
  • 11 Oct 2018 Status changed from suspended to discontinued.
  • 23 Jul 2012 Interim results were presented at the 8th International Conference on Head and Neck Cancer in Toronto.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top